The Ministry of Health of Kazakhstan and AstraZeneca signed a plan to implement an investment project to manufacture biotechnological drugs

During the visit of British Foreign Secretary David Cameron, a signing ceremony was held for the Plan to implement the AstraZeneca’s investment to manufacture biotechnology drugs in Kazakhstan. The Minister of Health of the Republic of Kazakhstan Akmaral Alnazarova and the management of British-Swedish company AstraZeneca Kazakhstan Maria Shipuleva, as well as the Managing director of "KAZAKH INVEST" JSC Azamat Kozhanov, and Deputy Akim of Almaty Abdykadyrov Alisher were present at the ceremony.

The signing of this plan on localization is a progressive step towards fulfilling the instructions of the President of Kazakhstan K. Tokayev. President of Kazakhstan K. Tokayev wants Kazakhstan to bring the share of domestically produced medicines in the domestic market up to 50% and AstraZeneca’s investment would play a key role in this.

At the end of 2023, the Ministry of Health of Kazakhstan and AstraZeneca Kazakhstan signed a roadmap for the project to localize the production of the company's drugs in the Republic. The signing of today's plan by the parties outlines the step-by-step actions of the parties to develop contract manufacturing of innovative medicines in the Republic of Kazakhstan. 

Maria Shipuleva, Director of AstraZeneca's Representative Office in Kazakhstan: "Today's signing of the Investment Project Implementation Plan is another important step towards our goal with a more concrete step-by-step plan to realize what was spelled out earlier in the Memorandum and Roadmap. We are confident that the contract manufacturing will enable the transfer of AstraZeneca's global competences and expertise in the production of complex innovative drugs to Kazakhstan".

Azamat Kozhanov, Managing Director of National Company KAZAKH INVEST JSC: “Investments from large international companies such as AstraZeneca improve the investment climate and attract other large companies to cooperate with Kazakhstan. The project for the contract production of biotechnological drugs strengthens Kazakhstan’s position as a reliable partner for foreign investors. We expect this project to be a catalyst for further growth of the biotechnology industry and attracting new investment to Kazakhstan.”

About AstraZeneca

AstraZeneca is an international innovative biopharmaceutical company focused on researching, developing, and bringing to market prescription medicines predominantly in therapeutic areas such as oncology, cardiology, nephrology and metabolism, respiratory and autoimmune, and rare diseases. Based in Cambridge, UK, AstraZeneca has a presence in more than 100 countries and its innovative medicines are used by millions of patients worldwide.